General Information of This Drug (ID: DMNS70E)

Drug Name
PHA-690509   DMNS70E
Synonyms
PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
PHA-690509 + Mitomycin DC2KIZ1 Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
PHA-690509 + PF-562271 DCA5DC5 PF-562271 Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
PHA-690509 + Ibrutinib DCUAESG Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
PHA-690509 + Ruxolitinib DCCKBMR Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
------------------------------------------------------------------------------------

References

1 Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6.
2 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
3 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976